Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

Key Takeaways Hims & Hers shares plunged nearly 35% Monday after Novo Nordisk said it is pulling Wegovy from the platform, ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...